Literature DB >> 23939409

Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex.

Ravindar R Thomas1, Paula M Keeney, James P Bennett.   

Abstract

Parkinson's disease (PD) can include a progressive frontal lobe α-synucleinopathy with disability from cognitive decline and cortico-limbic dysregulation that may arise from bioenergetic impairments. We examined in PD frontal cortex regulation of mitochondrial biogenesis (mitobiogenesis) and its effects on Complex-I. We quantified expression of 33 nuclear genome (nDNA)-encoded and 7 mitochondrial genome (mtDNA)-encoded Complex-I genes, 6 Complex-I assembly factors and multiple mitobiogenesis genes. We related these findings to levels of Complex-I proteins and NADH-driven electron flow in mitochondria from these same specimens reported in earlier studies. We found widespread, decreased expression of nDNA Complex-I genes that correlated in some cases with mitochondrial Complex-I protein levels, and of ACAD9, a Complex-I assembly factor. mtDNA-transcribed Complex-I genes showed ~ constant expression within each PD sample but variable expression across PD samples that correlated with NRF1. Relationships among PGC-1α and its downstream targets NRF1 and TFAM were very similar in PD and CTL and were related to mitochondrial NADH-driven electron flow. MicroRNA arrays revealed multiple miRNA's regulated >2-fold predicted to interact with PGC-1α or its upstream regulators. Exposure of cultured human neurons to NO, rotenone and TNF-alpha partially reproduced mitobiogenesis down-regulation. In PD frontal cortex mitobiogenesis signaling relationships are maintained but down-regulated, correlate with impaired mitochondrial NADH-driven electron flow and may arise from combinations of nitrosative/oxidative stresses, inflammatory cytokines, altered levels of mitobiogenesis gene-interacting microRNA's, or other unknown mechanisms. Stimulation of mitobiogenesis in PD may inhibit rostral disease progression and appearance of secondary symptoms referable to frontal cortex.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23939409     DOI: 10.3233/JPD-2012-11074

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  17 in total

Review 1.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 2.  MicroRNAs in Parkinson's disease.

Authors:  Abhishek Singh; Dwaipayan Sen
Journal:  Exp Brain Res       Date:  2017-05-19       Impact factor: 1.972

Review 3.  Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases.

Authors:  Gilles Bonvento; Julien Valette; Julien Flament; Fanny Mochel; Emmanuel Brouillet
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-09       Impact factor: 6.200

Review 4.  Nrf2/ARE Pathway as a Therapeutic Target for the Treatment of Parkinson Diseases.

Authors:  Artem P Gureev; Vasily N Popov
Journal:  Neurochem Res       Date:  2019-01-07       Impact factor: 3.996

Review 5.  Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Authors:  Masayuki Nakamori; Eunsung Junn; Hideki Mochizuki; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 6.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

7.  Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.

Authors:  Yanshi Hu; Zhenhua Pan; Ying Hu; Lei Zhang; Ju Wang
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

8.  Mitochondrial oxidative phosphorylation transcriptome alterations in human amyotrophic lateral sclerosis spinal cord and blood.

Authors:  Amy C Ladd; Paula M Keeney; Maria M Govind; James P Bennett
Journal:  Neuromolecular Med       Date:  2014-08-01       Impact factor: 3.843

Review 9.  Preconditioning as a potential strategy for the prevention of Parkinson's disease.

Authors:  Mojtaba Golpich; Behrouz Rahmani; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-04-03       Impact factor: 5.590

10.  Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α.

Authors:  Elizabeth K Lucas; Courtney S Reid; Laura J McMeekin; Sarah E Dougherty; Candace L Floyd; Rita M Cowell
Journal:  Front Cell Neurosci       Date:  2015-01-06       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.